Tannic Acid Inhibits Hepatitis C Virus Entry into Huh7.5 Cells

Shuanghu Liu1,2☯, Ren Chen2☯, Curt H. Hagedorn2,3,4,5*

1 Department of Medicinal Chemistry, College of Pharmacy, University of Utah, Salt Lake City, UT, United States of America, 2 Department of Medicine, University of Utah, Salt Lake City, UT, United States of America, 3 Department of Medicine, University of Arkansas for Medical Sciences Little Rock, AR, United States of America, 4 Program in Genetics, University of Arkansas for Medical Sciences Little Rock, AR, United States of America, 5 The Central Arkansas Veterans Healthcare System, Little Rock, AR, United States of America

☯ These authors contributed equally to this work.
* chhagedorn@uams.edu

Abstract

Chronic infection with the hepatitis C virus (HCV) is a cause of cirrhosis and hepatocellular carcinoma worldwide. Although antiviral therapy has dramatically improved recently, a number of patients remain untreated and some do not clear infection with treatment. Viral entry is an essential step in initiating and maintaining chronic HCV infections. One dramatic example of this is the nearly 100% infection of newly transplanted livers in patients with chronic hepatitis C. HCV entry inhibitors could play a critical role in preventing HCV infection of newly transplanted livers. Tannic acid, a polymer of gallic acid and glucose molecules, is a plant-derived polyphenol that defends some plants from insects and microbial infections. It has been shown to have a variety of biological effects, including antiviral activity, and is used as a flavoring agent in foods and beverages. In this study, we demonstrate that tannic acid is a potent inhibitor of HCV entry into Huh7.5 cells at low concentrations (IC50 5.8 μM). It also blocks cell-to-cell spread in infectious HCV cell cultures, but does not inhibit HCV replication following infection. Moreover, experimental results indicate that tannic acid inhibits an early step of viral entry, such as the docking of HCV at the cell surface. Gallic acid, tannic acid’s structural component, did not show any anti-HCV activity including inhibition of HCV entry or replication at concentrations up to 25 μM. It is possible the tannin structure is related on the effect on HCV inhibition. Tannic acid, which is widely distributed in plants and foods, has HCV antiviral activity in cell culture at low micromolar concentrations, may provide a relative inexpensive adjuvant to direct-acting HCV antivirals and warrants future investigation.

Introduction

Chronic hepatitis C virus (HCV) infection is a major cause of chronic liver disease and hepatocellular carcinoma (HCC) [1–3]. An estimated 3% of the world’s population is chronically infected with HCV (1). No vaccine is currently available; although treatments have undergone
major improvements there remain needs for further advancements [4, 5]. Although HCV protease inhibitors and other direct-acting antiviral (DAA) agents have markedly improve the overall sustained virological response (SVR) following therapy, a significant proportion of patients with chronic hepatitis C remain unable to be treated with these regimens [6, 7]. The majority of new direct-acting antivirals target the replication step of HCV. Because of the high genetic heterogeneity of HCV and its rapid replication, monotherapy with DAA agents poses a high risk for selection of resistant variants and combinations of drugs targeting different steps of the viral life cycle, including virus entry, would likely improve viral response rates across a wider range of HCV genotypes and clinical settings [8].

HCV is a member of the Flaviviridae, has a 9.6 kb positive-stranded RNA genome, encodes for a single polyprotein cleaved by cellular and viral proteases into 10 different proteins: core, E1, E2, p7, and the nonstructural proteins, NS2, NS3, NS4A, NS4B, NS5A, and NS5B [9, 10]. The E1 and E2 (envelope) glycoproteins play a central role in virus entry into the hepatocytes which is a complex multistep process [11, 12]. At least four entry factors, including scavenger receptor class B type 1, tetraspanin cluster of differentiation (CD) 81, claudin-1, and occluding are sequentially involved after virus binding and HCV entry is via clathrin-mediated endocytosis [13, 14]. Attractive targets for cell entry antivirals include blocking virus-target cell interactions during attachment, post-binding events or viral fusion, any of which could provide complementary mechanisms of action to DAAs [15, 16].

HCV pseudo-particles, which consist of retroviral or lentiviral cores surrounded by an envelope containing HCV E1 and E2, have provided a valuable system to study viral and cellular determinants of the entry pathway [17, 18]. The establishment of an infectious HCV cell culture system (HCVcc) with a genotype 2a isolate (JFH1 strain) of HCV and Huh7 cells was critical in better understanding HCV entry [19, 20]. These systems allowed a number of HCV entry inhibitors to be identified [21–24], such as anti-CD81 antibodies and entry inhibitor 1 (EI-1) which blocks viral fusion [22,24].

Tannic acid is a plant-derived hydrolysable tannin polyphenol that is a gallic acid polymer glucoside (C_{76}H_{52}O_{46}, 1,701.20 Da) (Fig 1A) [25]. It is widely distributed in the plant kingdom, including food grains, fruits, herbs, vegetable and beverages such as tea, red wine, and coffee [26–28]. Tannic acid has been claimed to have a variety of beneficial effects on health that are believed to be primarily related to its antioxidant properties [29, 30]. Tannic acid inhibits the proliferation of different cancer cell lines [31, 32] and induces cancer cell apoptosis [33–35]. It enhanced the survival rate of mice bearing syngeneic tumors when given in drinking water [36]. Other studies have shown that tannic acid prevents azidothymidine (AZT) induced hepatotoxicity in mice [37]. Antiviral activities of tannic acid have been reported and are generally thought to be due to interference with viral adsorption to the host cell membrane and not antioxidant properties (e.g., HIV, Bovine adeno-associated virus and Noroviruses) [31, 38–40]. In addition a recent report showed tannic acid can inhibit the attachment of Influenza A and Human papillomavirus at relatively low concentrations (41). However, it is unknown whether it has any effect against HCV.

The green-tea polyphenol, epigallocatechin-3-gallate (EGCG), which is one type of tannin, was reported to inhibit HCV entry [42, 43]. Tannic acid, a common tannin, is structurally similar to EGCG [25, 26, 44, 45]. We hypothesized that tannic acid may have anti-HCV activities and tested this hypothesis in an infectious HCV cell culture system. In this report we provide evidence that tannic acid inhibits HCV entry and cell-to-cell transmission but does not interfere with intracellular HCV replication. Tannic acid is widely distributed in food and beverages, is present in blood and tissues, and may be a natural barrier to HCV infection.
Materials and Methods

2.1 Cell culture

Human hepatoma cells, Huh7.5, were generously provided by Dr. Charles M. Rice [46] and maintained in Dulbecco’s modified Eagle’s medium (DMEM) (Invitrogen) supplemented with 100 U/ml of penicillin, 100 μg/ml of streptomycin, nonessential amino acids, and 10% fetal bovine serum (FBS) (Invitrogen) at 37°C in 5% CO2. All experiments described in this study were performed using these cells.

2.2 Antibodies

The monoclonal antibody to the NS5A protein (9E10) was a gift from Dr. Charles Rice (Rockefeller University). The monoclonal antibody against the HCV NS3 protein (Abcam, MA, USA), goat anti-mouse conjugated with horseradish peroxidase (HRP) (Sigma) and goat anti-mouse IgG conjugated with Alexa Fluor 594 (Invitrogen) were obtained commercially.
2.3 Test compounds

Tannic acid was obtained from MP Biomedicals LLC, Solon, OH, USA and Post Apple Scientific Inc., North East, PA, USA. Tannic acid was dissolved in deionized water and sterilized using a 0.22 μM filter unit (Millipore) and 5 mM stock solutions were prepared. Heparin and gallic acid were purchased from Sigma-Aldrich and dissolved in water and sterilized in the same way to produce stock concentrations of 500 mg and 5 mM, respectively.

2.4 Preparation of stock HCV JFH1-AM120 Renilla luciferase (JFH1-AM120-Rluc) reporter virus

The JFH1-AM120-Rluc reporter virus has been described previously [19, 47]. To generate the full-length genomic RNA, JFH1-AM120-Rluc was linearized at the 3' end of the HCV cDNA with XbaI. The linearized plasmid DNA was purified and used as a template for T7 in vitro transcription (MEGAscript, Ambion). In vitro transcribed RNA was transfected into cells by electroporation as described previously [48, 49]. Media containing virus was collected, clarified by low speed centrifugation (1,500 x g for 10 minutes), and stored at -80°C. HCV titers were determined by infection of Huh7.5 cells with serial dilutions of virus, followed by indirect immunofluorescence for HCV NS5A protein as described below and expressed as focus forming units (ffu)/ml. Several passages of infected cells were required to generate high titer stocks of virus.

2.5 Immunofluorescence Assays (IFA)

Cells infected with HCV were washed with PBS, fixed with 4% paraformaldehyde, and permeabilized with 0.2% Triton X-100. Fixed cells were blocked with 1% bovine serum albumin and 1% normal goat serum in PBS. HCV NS5A protein in cells was detected by incubation with an NS5A-specific monoclonal antibody and visualized with the secondary goat anti-mouse IgG conjugated to Alexa Fluor 594 dye (Life Technologies, 1:1,000 dilutions). Cover slips were mounted onto slides with DAPI (Vector Labs) and the HCV proteins were visualized by fluorescence microscopy (Nikon E400).

2.6 Titration of Infectious HCV

The titer of infectious HCV preparations was determined by IFA assays of inoculated cells, where the number of NS5A positive cell foci were determined as previously described [20]. Cell supernatants were serially diluted 10-fold in DMEM. The supernatants were used to infect 1x10⁴ naïve Huh7.5 cells in 96-well plates. Cells were incubated with virus for 2h at 37°C, washed and incubated with complete DMEM. The level of HCV infection was determined three days post infection by immunofluorescence staining for NS5A. Viral titers are expressed as focus-forming units per milliliter of supernatant (ffu/ml).

2.7 Western Blot Analysis

The HCV infected or transfected Huh7.5 cells were lysed in a radioimmunoprecipitation assay (RIPA) buffer (50 mM Tris-HCl, pH 7.5, 150 mM NaCl, 1% Nonidet P40, 0.5% sodium deoxycholate) containing a cocktail of protease inhibitors (Roche). The total protein for each sample was measured using a standard protein assay (Bio-Rad). Twenty micrograms of total protein of each sample was analyzed by 8% SDS-PAGE and transferred to nitrocellulose membranes. The membranes were blocked with 5% skim milk. HCV proteins were detected with a monoclonal antibody specific for NS3, horseradish peroxidase-conjugated goat anti-mouse...
immunoglobulin G (Bio-Rad) and a chemiluminescence substrate (Pierce). Actin was used as a
control and was detected with an anti-β-actin monoclonal antibody (Sigma).

2.8 The Effect of Tannic Acid on HCV 1b Replicons
The HCV 1b replicon Con1/SGNeo (I) plasmid was a gift from Dr. Charles Rice (Rockefeller
University) [50]. The plasmid was linearized with ScaI and in vitro transcription was per-
formed as described previously [46]. HCV 1b replicon RNA was electroporated into Huh7.5
cells and seeded into six-well plates and cultured for 48 hours. Cells were trypsinized, subcul-
tured into twelve-well plates and the tannic acid at concentrations of 0 μM, 3.1 μM, 6.3 μM,
12.5 μM and 25 μM was added the following day. The cells were then culture with tannic acid
for 48 hours. Mock electroporation (no HCV1b replicon RNA) of cells provided controls. Cells
were lysed in RIPA buffer and Western blots were done with anti-NS3 monoclonal antibodies.

2.9 Quantification of HCV RNA by qPCR
Huh7.5 cells in twelve-well plates were infected with HCV JFH1-AM120-Rluc for 2 hours in
the presence of the described concentrations of tannic acid; cells were washed with PBS and
were incubated for 48 hours under standard conditions. Total RNA was extracted with Trizol
(Invitrogen) and HCV RNA was measured by qPCR analysis as described previously [51]. The
relative quantity of HCV RNA in control and HCV samples was calculated using the compara-
tive Ct (cycling threshold) method. A reference gene (β-actin) was used as a control.

2.10 Renilla Luciferase Reporter Assay for the inhibition of HCV infection
Huh 7.5 cells were grown overnight in 96-well plates under standard conditions. Cells were
infected for 2 hours with HCV JFH-AM120-Rluc at a multiplicity of infection (MOI) of 0.1
with or without compounds. At 48 hours post-inoculation the cells were treated with lysis
buffer at room temperature for 15 minutes. Renilla luciferase (Rluc) activity was measured in
cell lysates using a Renilla luciferase Assay System kit (Promega) and microplate reader (Bio-
Tek). Normalized luciferase activity was plotted as a function of inhibitor concentration and
IC50 values were calculated from a linear fit of the inhibitor data.

2.11 Toxicity assays of tannic acid
Cell viability was determined using a CellTiter 96 Aqueous One solution cell proliferation
assay kit (Promega) following the manufacturer’s instructions. Briefly, aliquots of 1 × 10^4
Huh7.5 cells/well were cultured in 96-well plates with fresh medium or medium with increasing
concentrations of Tannic acid for 48 and 72 hours. CellTiter 96 Aqueous One solution
(40 μl, Promega) was added to each well and incubated for 3 hours. The absorbance at 490 nm
was measured with a 96-well plate reader. Each experiment was performed in triplicate and
repeated at least three times. The concentration of 50% cellular cytotoxicity (CC50) of tannic
acid was determined as the drug concentration that yielded 50% cell death using MS-Excel soft-
ware. Possible direct effects of tannic acid on Renilla luciferase was examined as follows.
JFH1-AM120-Rluc infected cell lysates containing Renilla luciferase were mixed with increasing
concentrations of tannic acid and incubated for 10 minutes at room temperature and lucif-
erase activity was measured as described above. Assays were done in triplicate and experiments
done three times.
2.12 Quantitative Binding Assay

Huh7.5 cells were inoculated with HCV JFH1AM120-Rluc at a MOI of 10 for 1 hour at 4°C in presence of 50 μM of tannic acid, or 500 μg/ml of heparin, no inhibitor as a control. Cells were washed twice with ice-cold PBS, and total RNA was extracted using the Trizol (Invitrogen) according to the manufacturer’s instructions. HCV RNA was quantified by quantitative real-time reverse transcription polymerase chain reaction (qRT-PCR) assay as described previously [51].

2.13 Entry Assay

JFH1-AM120-Rluc virus binding to target Huh7.5 cells was performed for 1h at 4°C in the absence or in the presence of compounds in 24-well plates. Subsequently, cells were washed with PBS and shifted to 37°C to allow entry to proceed. Depending on the protocol, inhibitors were added directly or 1, 2 or 3 h thereafter (II, III, and IV, respectively) and incubated in complete culture medium at 37°C for 48 hours. Infections were scored by measuring luciferase activity.

2.14 HCV Cell-to-Cell Transmission Assay

An assay incorporating a semisolid medium was used to measure cell-to-cell spread of HCV infection [52]. HCV was added to Huh7.5 cells at a MOI of 0.005 ffu/cell and incubated at 37°C. After three hours of infection, the inoculum was removed and replaced with culture medium containing 1% low melting temperature agarose (Invitrogen) and 25 μM tannic acid or an equivalent volume of water as a control. To prevent the agarose from drying, 200 μl of complete DMEM was used to cover the agarose layer. Cells were incubated at 37°C for 3 days at which time the agarose was removed and the infected cells were analyzed by indirect immunofluorescence for the HCV NS5A as described above. The mean number of infected cells/ffu was determined from 20 foci.

2.15 Statistical analysis

The mean and standard deviation of the mean (SD) for datasets were determined and the results for different experimental conditions (e.g., inhibitor or no inhibitor) were compared using the Students t-test. A P value < 0.05 was considered to be significant.

Results

3.1 Toxicity Assays of Tannic Acid

Tannic acid (C_{76}H_{52}O_{46}) is a polyphenol that is highly soluble in water (Fig 1A). Before testing the hypothesis that tannic acid had HCV antiviral effects, we first determined the cytotoxicity of tannic acid on Huh7.5 cells. Cytotoxicity was measured using a CellTiter 96 Aqueous One solution cell proliferation assay kit (Promega) according to the manufacturer’s instructions. Tannic acid at concentrations of less 50 μM showed no toxic effects on cells after 48 hours of incubation (Fig 1B). The CC_{50} of tannic acid for cultured Huh7.5 cells was 146.1 ± 6.2 μM at 48 and 126.9±15.3 μM at 72 hours. Although luciferase reporter enzymes can speed the evaluation of antiviral compounds, they can also be directly inhibited by some compounds leading to false positives in screening tests [53]. To determine whether tannic acid directly inhibited Rluc activity, lysates of JFH1-AM120Rluc infected cells expressing Rluc protein was mixed with increasing concentrations of tannic acid for 10 minutes at room temperature and luciferase activity was measured. The result showed that tannic acid did not directly inhibit Rluc activity at concentrations less than 50 μM (Fig 1C).
3.2 Effect of Tannic Acid on HCV Infection

The structure of tannic acid is similar to epigallocatechin-3-gallate epigallocatechin-3-gallate (EGCG) and previous studies have demonstrated EGCG has anti-HCV activity by blocking HCV entry \[30, 54, 42, 43\]. We hypothesized that tannic acid may have a similar effect on HCV. To confirm this hypothesis, we used an infectious chimeric HCV cell culture system expressing Renilla luciferase (JFH1-AM120-Rluc) to infect cells (MOI = 0.1) in the presence of increasing concentrations of tannic acid \[47\]. After two hours of infection, the inoculum was removed; cells were washed with PBS and incubated for 48 hours. Cells were lysed and luciferase activity was measured as described in Materials and Methods. Tannic acid produced a dose-dependent decrease in HCV infection as measured by Rluc activity (Fig 2A). The inhibitory effect of tannic acid was also tested with HCV at an MOI of 0.01, 0.2 and 0.5. The results showed a similar dose response with this range of MOIs (Data not showed). The IC\(_{50}\) for tannic acid was 5.8 ± 0.38 μM and the therapeutic index was approximately 25. To verify that changes observed after tannic acid treatment indeed reflected changes in HCV infection, the HCV NS3 protein and HCV RNA were measured after HCV infection and tannic acid treatment by

![Tannic acid inhibits HCV infection.](https://example.com/image.png)

**Fig 2. Tannic acid inhibits HCV infection.** (A) The effect of tannic acid on an infectious HCV cell culture system. Huh7.5 cells in 96 well plates were infected with HCV JFH1-AM120-Rluc for two hours in the presence of the specified concentrations of tannic acid, cells were washed with PBS and incubated for 48 hours. Cells were lysed and luciferase activity was measured as described in Materials and Methods. The results for three experiments are shown as mean RLUs ± SD of triplicate cell culture assays in 96-well plates. The IC\(_{50}\) was 5.8 ± 0.38 μM. (B) The effect of tannic acid on the production of HCV NS3 protein. Huh7.5 cells were infected with JFH1-AM120-Rluc for two hours in the presence of the specified concentrations of tannic acid, cells were washed with PBS and incubated for 48 hours. Cells were lysed and Western blotting was done with anti-HCV NS3 antibodies as described in Materials and Methods. The image represents three different experiments. (C) The effect of tannic acid on the production of HCV RNA. Huh7.5 cells were infected with JFH1-AM120-Rluc for two hours in the presence of the specified concentrations of tannic acid, cells were washed with PBS and incubated for 48 hours. The total RNA was extracted and qPCR assays for HCV RNA were done as described in Materials and Methods. Error bars represent the mean ± SD of results from three experiments.

doi:10.1371/journal.pone.0131358.g002
Western blotting and qPCR, respectively. Both of the NS3 protein (Fig 2B) and HCV RNA levels (Fig 2C) decreased in a dose dependent manner that corresponded to changes in Rluc activity, supporting the antiviral activity of tannic acid. Similar results were found when tannic acid from two other suppliers was tested (see Materials and Methods) (data not shown).

3.3 Tannic Acid Inhibits an Early Step of HCV Infection

To identify which step of HCV infection tannic acid inhibited, tannic acid 25 μM was added to Huh7.5 cells before, during, and after inoculation with HCV JFH1-AM120-Rluc. Tannic acid was added to the culture medium of Huh7.5 cells for 2 hours before JFH1-AM120-Rluc virus infection (pretreatment), for two hours during infection with the JFH1-AM120-Rluc virus (during infection), and for two hours after infection with JFH1-AM120-Rluc (post infection). Forty-eight hours post infection, cells were lysed and luciferase activity was measured. Infectivity is expressed as a percentage relative to the luciferase activity measured in controls not treated with tannic acid. Mock Infection with conditional medium served as a negative control. Interestingly, HCV infection was inhibited only when tannic acid was present during virus infection and tannic acid had no effect if added before or after HCV infection (Fig 3). These results suggested that tannic acid inhibited a relatively early step in the HCV life cycle, such as viral entry.

3.4 Effect of Tannic Acid on HCV Replication

After determining the antiviral activity of tannic acid in an infectious HCV cell culture system, we sought to analyze the antiviral mechanism of tannic acid using a sub-genomic HCV 1b replicon cell culture system. This system only displays HCV intracellular replication and does not

![Graph](image)

**Fig 3. Tannic acid inhibits an Early Step of HCV Infection.** Tannic acid 25μM was added to the culture medium of Huh7.5 cells for two hours before infection (pre-treatment), for two hours during infection (during-infection), and for two hours after infection with JFH1-AM120Rluc virus (post infection). Forty-eight hours post infection, cells were lysed and luciferase activity was measured. Infectivity is expressed as a percentage relative to luciferase activity measured in controls without tannic acid. Mock infection was the negative control. Mean values ± SD of three different experiments done in triplicate are presented. Results with a Student’s t-test P value < 0.01 are indicated by an asterisk.

doi:10.1371/journal.pone.0131358.g003
exhibit viral entry, assembly and release steps. HCV 1b replicon RNA was electroporated into Huh7.5 cells and seeded into twelve-well plates. Six hours post-electroporation, tannic acid at concentrations of 0 μM, 3.1 μM, 6.3 μM, 12.5 μM and 25 μM was added and cells were cultured for 48 hours as described in Materials and Methods. Mock electroporation (no HCV 1b replicon RNA) of cells provided controls. Cells were lysed and Western blots were done with anti-NS3 monoclonal antibodies as described in Materials and Methods. Immunoblotting for HCV NS3 showed no decrease at the concentrations of tannic acid tested (Fig 4), providing evidence that tannic acid does not inhibit HCV replication.

3.5 Tannic Acid Blocks an Early Step of HCV Entry

The mechanism of HCV entry is a complex multistep process involving binding of viral particles to the cell surface, interaction with entry factors followed by endocytosis and fusion of the viral envelope with an internal membrane [12]. Because our initial analysis provided evidence that tannic acid inhibited an early step of the HCV life cycle, we conducted studies aimed at identifying which step of viral entry was impaired. Previous studies demonstrated that at 4°C...
HCV attaches to cells but does not efficiently enter cells and at 37°C the virus enter cells via endocytosis and membrane fusion [21]. To determine which step of HCV entry was impaired, tannic acid was added at different times when HCV JFH1-AM120-Rluc was allowed to bind to Huh7.5 cells at 4°C (1 hour) and cells were subsequently incubated at 37°C (Fig 5A). Heparin, a known inhibitor of HCV binding, was used as a positive control [21]. A strong decrease in HCV infection was observed when tannic acid was present during the one hour 4°C binding step, whereas no inhibition was observed when tannic acid was added after virus binding. As expected, similar results were obtained when heparin was added during the 4°C binding step, but had no effect if added following this step (Fig 5B).

To determine whether tannic acid directly impaired the binding of HCV particles to the cell surface or a later step of virus entry, we analyzed virus binding in the presence of tannic acid. Huh7.5 cells were inoculated with HCV JFH1-AM120-Rluc for one hour at 4°C in the presence of tannic acid or heparin and inoculated cells without inhibitors provided controls. After one hour cells were washed with PBS, RNA was extracted from cells using Trizol and the amount of bound HCV was measured by qPCR assays of HCV RNA. As expected, heparin strongly reduced HCV attachment to the cell surface as measured by HCV RNA qPCR assays (Fig 5C). In the presence of tannic acid, a marked decrease in virus binding was also observed as compared to controls.

These results provide evidence that tannic acid most likely has an antiviral effect by inhibiting the binding of HCV to the cell surface.

To further investigate if tannic acid affects viral particles or cells, infectious HCV particles were preincubated with tannic acid before their use in inoculating Huh7.5 cells. If tannic acid acts directly on HCV particles, the preincubation treatment of HCV was predicted to have a marked inhibitory effect on infection. Preincubation of the virus with 50 μM of tannic acid, followed by dilution to 5 μM during infection, led to a stronger inhibition of infection than that observed with 5 μM of tannic acid during inoculation without any preincubation (Fig 5D).

These data provide evidence that tannic acid inhibits HCV entry by a direct effect on HCV particles.

### 3.6 Effect of Tannic Acid on Cell-to-cell Spread of HCV

Following infection of Huh7.5 cells with HCV the transmission of progeny virus to adjacent cells results in localized collections of infected cells called foci. To determine whether tannic acid could block the cell-to-cell spread of HCV, Huh7.5 cells were infected with an MOI 0.005 of HCV. At two hours post infection the inoculum was removed and replaced with culture medium containing 1% low melting temperature agarose with tannic acid 25 μM or without tannic acid (controls). Cells were incubated at 37°C for three days at which time the agarose was removed and the infected cells were detected using immunofluorescence assays for the HCV NS5A protein as described in Materials and Methods. Foci were visualized by immunofluorescence microscope (Fig 6A) and size of foci was measured by counting the number of cells per foci present in randomly selected fields for each condition (Fig 6B). Tannic acid produced a marked reduction in the number of cells per focus forming unit (average of seven cells per focus) as compared to the control conditions (average of 20 cells per focus) (p = 0.00058). These results provide evidence that tannic acid prevents in vitro HCV cell-to-cell transmission.

### 3.7 Effect of Gallic Acid on HCV Infection

Tannic acid is relatively large molecule that can be broken down into smaller gallic acid and glucose components [25, 41]. To determine whether gallic acid also inhibited HCV entry in our system, Huh7.5 cells were infected with the HCV JFH1-AM120-Rluc in the presence of
Fig 5. Tannic acid blocks an early step of HCV entry. (A) Schematic drawing of the experiment design. Inhibition of HCV JFH1-AM120-Rluc entry into Huh7.5 cells by tannic acid (25 μM) and heparin controls.
this system up to concentrations of 25 μM. As expected, gallic acid did not inhibit HCV replication in
a number of biological properties that have suggested health benefits and have been used to
enhance farm animal growth [31, 38, 40]. To our knowledge, our results provide the first evi-
dence that tannic acid is a potent inhibitor of HCV entry into Huh7.5 cells, possibly at the
docking of the virus to the cell surface step, at relatively low concentrations (IC50 5.8 μM). As

Increasing concentrations of gallic acid. Tannic acid was also tested as a control. After two
hours infection (37°C) the inoculum was removed, cells were washed and fresh complete
medium was added. At 48 hours of incubation cells were lysed and luciferase activity was mea-
sured to assay for HCV infection. A dose-dependent decrease of Rluc activity was observed in
tannic acid treated cells, but no effect was observed in gallic acid treated cells indicating that it
did not inhibit HCV entry (Fig 7A). To determine if gallic acid inhibited HCV replication,
Huh7.5 cells were infected with the HCV JFH1-AM120-Rluc for two hours, cells were washed and increasing concentrations of gallic acid (0 to 25 μM) were added. Tannic acid was used as a
control. The cells were incubated for 48 hours and Rluc activity was measured. These results
provide evidence that gallic acid had no detectable anti-HCV activity during HCV entry and
replication steps at concentrations of 0 to 25 μM (Fig 7B).

Higher concentrations of gallic acid were tested in the HCV JFH1-AM120-Rluc cell culture
system, during and after inoculation as above, and no inhibition was seen 50 μM (data not
shown). Concentrations of gallic acid ≥100 μM produced confounding effects on the pH of the
cell culture medium, making it difficult to determine a true IC50 and CC50. The effect of gallic
acid was also tested using a sub-genomic HCV 1b replicon cell culture system following the
methods described for tannic acid. As expected, gallic acid did not inhibit HCV replication in
this system up to concentrations of 25 μM (Fig 7C and 7D).

Discussion
Tannins are a unique group of phenolic compounds found in plants with molecular weights
between 500 and 30,000 Da and are widely distributed in foods and beverages [25, 26]. Tannic
acid, a member of this class of compounds, is present in many cereals, legumes, fruits, herbs and beverages such as tea, red wine, coffee [26–28]. Tannins in plants are believed to play an
important role in protecting them against insect and microbial infections. Tannic acid exhibits
a number of biological properties that have suggested health benefits and have been used to
enhance farm animal growth [31, 38, 40]. To our knowledge, our results provide the first evi-
dence that tannic acid is a potent inhibitor of HCV entry into Huh7.5 cells, possibly at the
docking of the virus to the cell surface step, at relatively low concentrations (IC50 5.8 μM). As
expected from a viral cell entry inhibitor, tannic acid also blocked the cell-to-cell spread of HCV in culture. However, it did not inhibit HCV replication. Interestingly, tannic acid has been found to inhibit the attachment of other viruses to host cells, including norovirus binding to HBGA receptors and the attachment of influenza A virus to cells with an EC₅₀ of 4.3 μM [39, 41]. The less widely distributed green-tea polyphenol tannin, epigallocatechin-3-gallate (EGCG), was demonstrated to inhibit HCV entry by blocking viral attachment to cells [42, 43]. The other tannins, such as EGCG, chebulagic acid and punicalagin have been suggested to have broad-spectrum antiviral activities [55]. Although the mechanisms of actions of
Fig 7. Comparison of the effect of gallic and tannic acid on HCV infection. (A) Effect during inoculation in an HCV cell culture system. HuH7.5 cells were infected with JFH1-AM120-Rluc for two hours in the presence of the specified concentrations of gallic or tannic acid, cells were washed and further incubated for 48 hours.
polyphenols, such as tannic acid, have primarily been considered to be due to their antioxidant activity, we suggest that their ability to prevent the entry of viruses into cells is more likely due to their ability to form macromolecular complexes on the cell surface [56, 57]. It is interesting to speculate that naturally occurring tannins in food and beverages, when consumed in appropriate quantities, may sometimes provide a barrier to pathogenic microorganisms in both humans and other mammals.

Studies of the metabolism of tannic acid in rats, mice, sheep and chickens indicate that gallic acid, 4-O-methylgallic acid, pyrogallol, resorcinol, and ellagic acid are the major metabolites generated from tannic acid [58–62]. However, the concentrations tannic acid in blood after meals or oral dosing and its metabolism in humans remain relatively unstudied. Interestingly, tannic acid consumed at doses of 150 mg per day by type II diabetic patients significantly decreased blood glucose levels compared to controls [63]. Nevertheless, despite the interest in possible therapeutic applications of dietary tannic acid and other polyphenols their safe levels of consumption remain to be fully defined.

HCV entry is a complex multistep process involving multiple cell-surface proteins and post-binding events [12, 15, 64]. Viral entry is an essential role in the pathogenesis of HCV infection, especially in sustaining chronic infection and during the infection of donor livers transplanted into patients with chronic hepatitis C [65, 66]. HCV cell entry inhibitors, in combination with direct-acting antivirals, might provide an effective means of preventing the infection of transplanted livers in the many patients with chronic hepatitis C receiving transplants. The combined use of hepatitis B immune globulin, a well characterized HBV entry inhibitor, with nucleotide analogues has essentially eliminated HBV recurrence in liver transplantation patients [67]. Although a number of HCV cell entry inhibitors have been reported in different systems, they represent a relatively undeveloped area of HCV antivirals [21–24]. Our results provide a rationale for further exploring the cell entry HCV antiviral activity of tannic acid and similar polyphenols as possible therapeutics for chronic hepatitis C.

Acknowledgments

We thank Dr. C.M. Rice for providing Huh7.5 cells and the anti-NS5A monoclonal antibody. R.C. was supported in part by a fellowship from Guangzhou General Hospital, Guangzhou, China. This work was supported in part by National Institutes of Health Grants CA148068 and CA176130 (CHH).
Author Contributions
Conceived and designed the experiments: CH SL RC. Performed the experiments: SL RC. Analyzed the data: CH SL RC. Wrote the paper: CH SL RC. Contributed equally in designing experiments, performing experiments and analyzing the data: SL RC.

References
1. Bialek SR, Terrault NA (2006) The changing epidemiology and natural history of hepatitis C virus infection. Clin Liver Dis 10:697–715. PMID: 17164113
2. Shepard CW, Finelli L, Alter MJ (2005) Global epidemiology of hepatitis C virus infection. Lancet Infect Dis 5:558–567. PMID: 16122679
3. Saito I, Miyamura T, Obayashi A, Harada H, Katayama T, Kikuchi S, et al. (1990) Hepatitis C virus infection is associated with the development of hepatocellular carcinoma. Proc Natl Acad Sci U S A 87:6547–6549. PMID: 2168552
4. Shina M, Rehermann B (2006) Hepatitis C vaccines: Inducing and challenging memory T cells. Hepatology 43:1395–1398. PMID: 16729320
5. Manns MP, Wedemeyer H, Cornberg M (2006) Treating viral hepatitis C: efficacy, side effects, and complications. Gut 55:1350–1359. PMID: 16905701
6. Asselah T, Marcellin P (2011) New direct-acting antivirals’ combination for the treatment of chronic hepatitis C. Liver Int 31 Suppl 1:68–77. doi:10.1111/j.1478-3231.2010.02411.x PMID: 21205141
7. Poordad F, McCone J Jr., Bacon BR, Bruno S, Manns MP, Sulkowski MS, et al. (2011) Boceprevir for untreated chronic HCV genotype 1 infection. N Engl J Med 364:1195–1206. doi:10.1056/NEJMoa1010494 PMID: 21205141
8. Sarrazin C, Zeuzem S (2010) Resistance to direct antiviral agents in patients with hepatitis C virus infection. Gastroenterology 138:447–456. doi:10.1053/j.gastro.2009.11.055 PMID: 20006612
9. Reed KE, Rice CM (2000) Overview of hepatitis C virus genome structure, polyprotein processing, and protein properties. Curr Top Microbiol Immunol 242:55–84. PMID: 10592656
10. Yi M, Ma Y, Yates J, Lemon SM (2007) Compensatory mutations in E1, p7, NS2, and NS3 enhance yields of cell culture-infectious intergenotypic chimeric hepatitis C virus. J Virol 81:629638.
11. Farquhar MJ, Harris HJ, McKeating JA (2011) Hepatitis C virus entry and the tetraspanin CD81. Biochem Soc Trans 39:532–536. doi:10.1042/BST0390532 PMID: 21428934
12. Bartosch B, Dubuisson J (2010) Recent advances in hepatitis C virus cell entry. Viruses 2:692709.
13. Blanchard E, Belouzard S, Goueslain L, Wakita T, Dubuisson J, Wychowski C, et al. 2006. Hepatitis C virus entry depends on clathrin-mediated endocytosis. J Virol 80:6964–6972. PMID: 16699011
14. Zeisel MB, Felmlée DJ, Baumert TF (2013) Hepatitis C virus entry. Curr Top Microbiol Immunol 369:87–112. doi:10.1007/978-3-642-27340-7_4 PMID: 23463198
15. Zeisel MB, Lupberger J, Fofana I, Baumert TF (2013) Host-targeting agents for prevention and treatment of chronic hepatitis C—perspectives and challenges. J Hepatol 58:375–384. doi:10.1016/j.jhep.2012.09.022 PMID: 23041307
16. Zeisel MB, Fofana I, Fafi-Kremer S, Baumert TF (2011) Hepatitis C virus entry into hepatocytes: molecular mechanisms and targets for antiviral therapies. J Hepatol 54:566–576. doi:10.1016/j.jhep.2010.01.014 PMID: 21146244
17. Bartosch B, Dubuisson J, Cosset FL (2003) Infectious hepatitis C virus pseudo-particles containing functional E1-E2 envelope protein complexes. J Exp Med 197:633–642. PMID: 12615904
18. Hsu M, Zhang J, Flint M, Logvinoff C, Cheng-Mayer C, Rice CM, et al. (2003) Hepatitis C virus glycoproteins mediate pH-dependent cell entry of pseudotyped retroviral particles. Proc Natl Acad Sci U S A 100:7271–7276. PMID: 12761383
19. Wakita T, Pietschmann T, Kato T, Date T, Miyamoto M, Zhao Z, et al. (2005) Production of infectious hepatitis C virus in tissue culture from a cloned viral genome. Nat Med 11:791–796. PMID: 15951748
20. Zhong J, Gastaminza P, Cheng G, Kapadia S, Kato T, Burton DR, et al. (2005) Robust hepatitis C virus infection in vitro. Proc Natl Acad Sci U S A 102:9294–9299. PMID: 15938969
21. Koutsoudakis G, Kaul A, Steinmann E, Kallis S, Lohmann V, Pietschmann T, et al. (2006) Characterization of the early steps of hepatitis C virus infection by using luciferase reporter viruses. J Virol 80:5308–5320. PMID: 16699011
22. Meuleman P, Hesselgesser J, Paulson M, Vanwolleghem T, Desombere I, Reiser H, et al. (2008) Anti-CD81 antibodies can prevent a hepatitis C virus infection in vivo. Hepatology 48:1761–1768. doi: 10.1002/hep.22547 PMID: 19030166
Tannic Acid Inhibits HCV Entry

23. Kirger SE, Zeisel MB, Davis C, Thumann C, Harris HJ, Schnober EK, et al. (2010) Inhibition of hepatitis C virus infection by anti-claudin-1 antibodies is mediated by neutralization of E2-CD81-claudin-1 associations. Hepatology 51:1144–1157. doi: 10.1002/hep.23445 PMID: 20696468

24. Baldick CJ, Wichtroski MJ, Pendri A, Walsh AW, Fang J, Mazzucco CE, et al. (2010) A novel small molecule inhibitor of hepatitis C virus entry. PLoS Pathog 6:e1001086. doi: 10.1371/journal.ppat.1001086 PMID: 20838466

25. Serrano J, Puupponen-Pimia R, Dauer A, Aura AM, Saura-Calixto F (2009) Tannins: current knowledge of food sources, intake, bioavailability and biological effects. Mol Nutr Food Res 53 Suppl 2:S310–329. doi: 10.1002/mnfr.200900039 PMID: 19437486

26. Okuda T, Yoshida T, Hatano T (1995) Hydrolyzable tannins and related polyphenols. Fortschr Chem Org Naturst 66:1–117. PMID: 8847006

27. Glick Z, Joslyn MA (1970) Food intake depression and other metabolic effects of tannic acid in the rat. J Nutr 100:509–515. PMID: 5443822

28. Liu X, Kim JK, Li Y, Li J, Liu F, Chen X (2005) Tannic acid stimulates glucose transport and inhibits adipocyte differentiation in 3T3-L1 cells. J Nutr 135:165–171. PMID: 15671208

29. Chung KT, Wong TY, Wei CI, Huang YW, Lin Y (1998) Tannins and human health: a review. Critical reviews in food science and nutrition 38:421–464. PMID: 9759559

30. Savolainen H (1992) Tannin content of tea and coffee. J Appl Toxicol 12:191–192. PMID: 1629514

31. Uchiumi F, Sato T, Tanuma S (1998) Identification and characterization of a tannic acidresponsive negative regulatory element in the mouse mammary tumor virus promoter. J Biol Chem 273:12499–12508. PMID: 9675208

32. Devi MA, Das NP (1993) In vitro effects of natural plant polyphenols on the proliferation of normal and abnormal human lymphocytes and their secretions of interleukin-2. Cancer Lett 69:191–196. PMID: 8513446

33. Sakagami H, Jiang Y, Kusama K, Atsumi T, Ueha T, Toguchi M, et al. (2000) Cytotoxic activity of hydrolyzable tannins against human oral tumor cell lines—a possible mechanism. Phytomedicine 7:39–47. PMID: 10782489

34. Pan MH, Lin JH, Lin-Shiau SY, Lin JK (1999) Induction of apoptosis by penta-O-galloyl-beta-D-glucose through activation of caspase-3 in human leukemia HL-60 cells. Eur J Pharmacol 381:171–183. PMID: 10554885

35. Wang CC, Chen LG, Yang L (2000) Cuphiin D1, the macrocyclic hydrolyzable tannin induced apoptosis in HL-60 cell line. Cancer Lett 149:77–83. PMID: 10737711

36. Koide T, Kamei H, Hashimoto Y, Kojima T, Hasegawa M (1999) Tannic acid raises survival rate of mice bearing syngeneic tumors. Cancer Biother Radiopharm 14:231–234. PMID: 10850307

37. Tikkoo K, Tamta A, Ali IY, Gupta J, Gaikwad AB (2008) Tannic acid prevents azidothymidine (AZT) induced hepatotoxicity and genotoxicity along with change in expression of PARG and histone H3 acetylation. Toxicol Lett 177:90–96. doi: 10.1016/j.toxlet.2007.12.012 PMID: 18291603

38. Di Pasquale G, Ostedgaard L, Veerme D, Swaim WD, Karp P, Chiorini JA (2012) Bovine AAV transcytosis inhibition by tannic acid results in functional expression of CFTR in vitro and altered biodistribution in vivo. Gene Ther 19:576–581. doi: 10.1016/j.agen.2011.11.040 PMID: 22285570

39. Ono K, Hasegawa K, Naiki H, Yamada M (2004) Anti-amyloidogenic activity of tannic acid and its activity to destabilize Alzheimer's beta-amyloid fibrils in vitro. Biochem Biophys Acta 1690:193202.
45. Ehmhoefner DE, Bieschke J, Boeddrich A, Herbst M, Masino L, Luzr R, et al. (2008) EGCG redirects amyloidogenic polypeptides into unstructured, off-pathway oligomers. Nat Struct Mol Biol 15:558–566. doi: 10.1038/nsmb.1437 PMID: 18511942

46. Blight KJ, McKeating JA, Rice CM (2002) Highly permissive cell lines for subgenomic and genomic hepatitis C virus RNA replication. J Virol 76:13001–13014. PMID: 12438626

47. Liu S, Xiao L, Nelson C, Hagedorn CH (2012) A cell culture adapted HCV JFH1 variant that increases viral titers and permits the production of high titer infectious chimeric reporter virus. PLoS One 7:e44965. doi: 10.1371/journal.pone.0044965 PMID: 23082707

48. Krieger N, Lohmann V, Bartenschlager R (2001) Enhancement of hepatitis C virus RNA replication by cell culture-adaptive mutations. J Virol 75:4614–4624. PMID: 11312331

49. Liu S, Chen R, Hagedorn CH (2014) Direct visualization of hepatitis C virus-infected Huh7.5 cells with a high titre of infectious chimeric JFH1-EGFP reporter virus in three-dimensional Matrigel cell cultures. J Gen Virol 95:423–433. doi: 10.1099/vir.0.055772-0 PMID: 24243732

50. Blight KJ, Kolykhalov AA, Rice CM (2000) Efficient initiation of HCV RNA replication in cell culture. Science 290:1972–1974. PMID: 11110665

51. Papic N, Maxwell CI, Delker DA, Liu S, Heale BS, Hagedorn CH (2012) RNA-sequencing analysis of 5’ capped RNAs identifies many new differentially expressed genes in acute hepatitis C virus infection. Viruses 4:581–612. doi: 10.3390/v4040581 PMID: 22590687

52. Timpe JM, Stamataki Z, Jennings A, Hu K, Farquhar MJ, Harris HJ, et al. (2008) Hepatitis C virus cell-cell transmission in hepatoma cells in the presence of neutralizing antibodies. Hepatology 47:17–24. PMID: 17941058

53. Auld DS, Thome N, Maguire WF, Inglese J (2009) Mechanism of PTC124 activity in cell-based luciferase assays of nonsense codon suppression. Proc Natl Acad Sci U S A 106:3585–3590. doi: 10.1073/pnas.0813345106 PMID: 19208811

54. Abe I, Umehara K, Morita R, Nemoto K, Degawa M, Noguchi H (2001) Green tea polyphenols as potent enhancers of glucocorticoid-induced mouse mammary tumor virus gene expression. Biochem Biophys Res Commun 281:122–125. PMID: 11178969

55. Lin LT, Chen TY, Lin SC, Chung CY, Lin TC, Wang GH, et al. (2013) Broad-spectrum antiviral activity of chebulagic acid and punicalagin against viruses that use glycosaminoglycans for entry. BMC Microbiol 13:187. doi: 10.1186/1471-2180-13-187 PMID: 23924316

56. Tsao R (2010) Chemistry and biochemistry of dietary polyphenols. Nutrients 2:1231–1246. doi: 10.3390/nu212133 PMID: 22254006

57. Le Bourvellec C, Renard CM (2012) Interactions between polyphenols and macromolecules: quantification methods and mechanisms. Critical reviews in food science and nutrition 52:213248.

58. Terrill TH, Waghor CM, Woolley DJ, McNabb WC, Barry TN (1994) Assay and digestion of 14C-labeled condensed tannins in the gastrointestinal tract of sheep. Br J Nutr 72:467–477. PMID: 7947660

59. Bravo L, Abia R, Eastwood MA, Saura-Calixto F (1994) Degradation of polyphenols (catechin and tannic acid) in the rat intestinal tract. Effect on colonic fermentation and faecal output. Br J Nutr 71:939–946. PMID: 8031740

60. Zhu J, Filippich LJ, MT AL (1992) Tannic acid intoxication in sheep and mice. Res Vet Sci 53:280292.

61. Potter DK, Fuller HL (1968) Metabolic fate of dietary tannins in chickens. J Nutr 96:187–191. PMID: 5681147

62. Zhu J, Filippich LJ, Ng J (1995) Rumen involvement in sheep tannic acid metabolism. Vet Hum Toxicol 37:436–440. PMID: 8592830

63. Gin H, Rigalleau V, Caubet O, Masquelier J, Aubertin J (1999) Effects of red wine, tannic acid, or ethanol on glucose tolerance in non-insulin-dependent diabetic patients and on starch digestibility in vitro. Metabolism 48:1179–1183. PMID: 10484061

64. Moyer K, Kwon Y-C, Liu S, Hagedorn CH, Ray RB, Ray R (2015) Interferon- inducible protein 6 impairs EGFR activation by CD81 and inhibits hepatitis C virus infection. Scientific Reports 5:9012. doi: 10.1038/srep09012 PMID: 25757571

65. Fafi-Kremer S, Fofana I, Soulier E, Carolla P, Meuleman P, Leroux-Roels G, et al. (2010) Viral entry and escape from antibody-mediated neutralization influence hepatitis C virus re-infection in liver transplantation. J Exp Med 207:2019–2031. doi: 10.1084/jem.20090766 PMID: 20715396

66. Fofana I, Fafi-Kremer S, Carolla P, Fauvelle C, Zahid MN, Turek M, et al. (2012) Mutations that alter use of hepatitis C virus cell entry factors mediate escape from neutralizing antibodies. Gastroenterology 143:223–233 e229. doi: 10.1053/j.gastro.2012.04.006 PMID: 22503792

67. Crespo GM, Marino Z, Navasa M, Foms X (2012) Viral hepatitis in liver transplantation. Gastroenterology 142:1373–1383 e1371. doi: 10.1053/j.gastro.2012.02.011 PMID: 22537446